Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.
Metrics to compare | 688221 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688221PeersSector | |
|---|---|---|---|---|
P/E Ratio | −42.9x | −17.0x | −0.6x | |
PEG Ratio | −1.07 | −0.42 | 0.00 | |
Price/Book | 7.3x | 5.2x | 2.6x | |
Price / LTM Sales | 50.9x | 17.3x | 3.3x | |
Upside (Analyst Target) | - | 27.4% | 41.4% | |
Fair Value Upside | Unlock | −14.0% | 6.0% | Unlock |